The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Rusfertide reduces cytoreductive therapy requirements in polycythemia vera
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, discusses a sub-analysis of the Phase III VERIFY study (NCT05210790) evaluating rusfertide in patients with phlebotomy-dependent polycythemia vera (PV). She explains how rusfertide reduced the need for higher doses of cytoreductive therapy while helping patients maintain hematocrit control, highlighting its potential role in the future management of PV. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We conducted a sub-analysis of a VERIFY Phase III clinical study, which included phlebotomy-dependent PV patients and randomized them to receive either rusfertide or placebo on top of standard of care. And in this sub-analysis, we wanted to analyze whether or not rusfertide could have any effect on the use of cytoreductive therapy. And what we observed is that around 40% of the patients included in the VERIFY study actually were on cytoreductive agents at the time of inclusion in the study...
We conducted a sub-analysis of a VERIFY Phase III clinical study, which included phlebotomy-dependent PV patients and randomized them to receive either rusfertide or placebo on top of standard of care. And in this sub-analysis, we wanted to analyze whether or not rusfertide could have any effect on the use of cytoreductive therapy. And what we observed is that around 40% of the patients included in the VERIFY study actually were on cytoreductive agents at the time of inclusion in the study. In 12% of the patients who were not on cytoreductive therapy, a cytoreduction was needed during the treatment. But what is more exciting and important is that we observed in a substantial fraction of patients a significant decrease of the dose of the cytoreduction that was required for achieving a good hematocrit control. So this is important because it allows the patient to reduce the dose of cytoreductive agents that may be burdensome in the long term and still achieve the hematocrit target below 45%.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
